Abiomed's Impella(R) Technology Showcased at TCT 2013 With Over 25 Accepted Presentations in the Scientific Sessions

Published on: October 24, 2013

Abiomed Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, notes that there will be over 25 potential Impella presentations in the scientific sessions at the Cardiovascular Research Foundation's (CRF) annual Transcatheter Cardiovascular Therapeutics (TCT) 2013 scientific meeting, scheduled from October 27 -- November 1, at the Moscone Convention Center in San Francisco, CA.

On the TCT show floor, Abiomed will conduct daily booth demonstrations at Abiomed booth #1307 and hands-on simulations of the Impella platform.

For further information about the TCT scientific program and the timing of scientific presentations, please contact Aimee Genzler, Corporate Communications Manager, at agenzler@abiomed.com or 978-646-1553.

Around the web

Radiology Business

Shift toward imaging outside the hospital could save billions

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

Cardiovascular Business

‘A significant milestone’: First US patients receive doses of new PET radiotracer for CAD

Back in September, the FDA approved GE HealthCare’s new PET radiotracer, flurpiridaz F-18, for patients with known or suspected CAD. It is seen by many in the industry as a major step forward in patient care.

Cardiovascular Business

Continuation of 99mTc-PYP shortage prompts need for alternative cardiac amyloidosis imaging

After three years of intermittent shortages of nuclear imaging tracer technetium-99m pyrophosphate, there are no signs of the shortage abating.

Abiomed's Impella(R) Technology Showcased at TCT 2013 With Over 25 Accepted Presentations in the Scientific Sessions

Related Content

Around the web